Xenon Pharmaceuticals (XENE) Cash & Equivalents (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Cash & Equivalents data on file, last reported at $545.9 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $545.9 million, up 367.92% year-over-year; the trailing twelve-month figure through Mar 2026 was $545.9 million (up 367.92% YoY), and the FY2025 annual result was $199.2 million, up 39.56% from the prior year.
• Cash & Equivalents grew to $545.9 million in Q1 2026 per XENE's latest filing, from $199.2 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $555.3 million in Q3 2025 and troughed at $57.2 million in Q4 2022.
• A 5-year average of $176.9 million and a median of $116.7 million in 2025 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents slumped 82.55% in 2023, then surged 533.7% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $57.2 million in 2022, then soared by 159.67% to $148.6 million in 2023, then fell by 3.99% to $142.7 million in 2024, then soared by 39.56% to $199.2 million in 2025, then soared by 174.08% to $545.9 million in 2026.
• Business Quant data shows XENE's Cash & Equivalents at $545.9 million in Q1 2026, $199.2 million in Q4 2025, and $555.3 million in Q3 2025.